Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Transl Oncol ; 23(4): 840-845, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32839927

RESUMEN

PURPOSE: To determine the presence of a group of mutations, and establish the prognostic value for recurrence and progression. MATERIALS AND METHODS: Prospective observational study. Intermediate-to-high-risk non-muscle invasive bladder cancer (NMIBC) was evaluated. Data from genetic analyses were included in a database along with clinicopathological variables of interest. RESULTS: Seventy-four patients. Twenty-five (33.8%) recurred and 3 (4.1%) progressed. Median time to recurrence: 8 months (5.7-12.7). Median time to progression: 14 months (P75: 12). Mutation distribution: KRAS codon 12: one patient (1.4%), BAT25: five patients (6.8%), BAT-26: four patients (5.4%), and D2S123: 6 patients (8.1%). Arg72Pro polymorphism: 50 patients (67.6%) exhibited homozygous mutations, 23 (31.1%) were heterozygous, and 1 patient (1.4%) did not present the mutation. We found an association between presence of MSI at BAT26 and female sex (p < 0.05) and tumor stage and the TP53 Arg72Pro polymorphism. Recurrence-free survival (RFS) was significantly associated with presence of MSI at D2S123, with a HR of 5.44 for patients presenting the mutation (95% CI 1.83-16.16). On multivariate analysis, we found a statistically significant increase in risk of recurrence among patients with MSI at D2S123 (HR 5.15; p < 0.05) and more than 2 previous transurethral bladder resections (TURBs) (HR 5.07; p < 0.05) adjusted for tumor stage and grade. Harrell's concordance index revealed an accuracy of 0.74 (p < 0.05). CONCLUSION: An association was found between presence BAT26 MSI and female sex, Arg72Pro polymorphism with tumor stage and D2S123 and more than 2 TUR procedures were associated with RFS adjusted to tumor stage and grade.


Asunto(s)
Biomarcadores de Tumor/genética , Progresión de la Enfermedad , Recurrencia Local de Neoplasia/genética , Mutación Puntual , Neoplasias de la Vejiga Urinaria/genética , Anciano , Análisis de Varianza , Codón/genética , Dipéptidos/genética , Femenino , Genes p53/genética , Genes ras , Marcadores Genéticos/genética , Humanos , Masculino , Inestabilidad de Microsatélites , Repeticiones de Microsatélite/genética , Pronóstico , Estudios Prospectivos , Factores Sexuales , Factores de Tiempo , Neoplasias de la Vejiga Urinaria/patología , Neoplasias de la Vejiga Urinaria/cirugía
2.
Bipolar Disord ; 17(1): 27-38, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25041243

RESUMEN

OBJECTIVES: The aim of this study was to evaluate the association of Val66Met brain-derived neurotrophic factor (BDNF) polymorphism with bipolar disorder in (i) a meta-analysis and (ii) a case-control study in a Mexican population. We also investigated the possible association of this polymorphism with clinical features. METHODS: We performed a keyword search of the PubMed and Web of Science databases. A total of 22 studies that have investigated the association of Val66Met (rs6265) with bipolar disorder were selected for inclusion and combined with random effects meta-analysis, using allelic, additive, dominant, and recessive models. Finally, the single nucleotide polymorphism (rs6265) Val66Met in the BDNF gene was genotyped and compared between 139 patients with bipolar disorder and 141 healthy volunteers in a Mexican population. RESULTS: The pooled results from the meta-analysis (9,349 cases and 7,437 controls) did not show a significant association in any of the models. The same results were obtained in our case-control study when analyzing the distribution of the genotypic frequencies of the Val66Met polymorphism in patients with bipolar disorder. However, when we analyzed the association between rs6265 and lifetime history of suicidal behavior, we found an association between genotype Val-Val and suicide attempt (p = 0.02). CONCLUSIONS: Although the present study has some limitations, the results indicate a lack of association between the Val66Met polymorphism and bipolar disorder. However, in our case-control study in a Mexican population, the Val66Met polymorphism was associated with suicidal behavior in patients with bipolar disorder. Nevertheless, it is important to consider potential interactions of the BDNF gene, the environment, and different inheritance patterns, when carrying out future genetic studies with larger samples.


Asunto(s)
Trastorno Bipolar/genética , Factor Neurotrófico Derivado del Encéfalo/genética , Dipéptidos/genética , Suicidio/psicología , Adulto , Trastorno Bipolar/epidemiología , Trastorno Bipolar/psicología , Estudios de Casos y Controles , Femenino , Genotipo , Humanos , Masculino , México/epidemiología , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Suicidio/estadística & datos numéricos
3.
Mov Disord ; 19(3): 324-30, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15022188

RESUMEN

Mutations in parkin are implicated in the pathogenesis of autosomal recessive juvenile parkinsonism (AR-JP) disease. We show that homozygote Cys212Tyr parkin mutation in AR-JP patients renders lymphocytes sensitive to dopamine, iron and hydrogen peroxide stimuli. Indeed, dopamine-induced apoptosis by four alternative mechanisms converging on caspase-3 activation and apoptotic morphology: (1) NF-kappaB-dependent pathway; mitochondrial dysfunction either by (2) H(2)O(2) or (3) hydroxyl exposure and (4) increase of unfolded-protein stress. We also demonstrate that 17beta-estradiol and testosterone prevent homozygote lymphocytes from oxidative stressors-evoked apoptosis. These results may contribute to understanding the relationship between genetic and environmental factors and iron in AR-JP.


Asunto(s)
Apoptosis/efectos de los fármacos , Dipéptidos/genética , Dopamina/metabolismo , Hierro/farmacología , Linfocitos/metabolismo , Trastornos Parkinsonianos/genética , Mutación Puntual/genética , Ubiquitina-Proteína Ligasas/genética , Análisis Mutacional de ADN , Femenino , Humanos , Masculino , Potenciales de la Membrana , Persona de Mediana Edad , FN-kappa B/genética , Trastornos Parkinsonianos/patología , Factores de Transcripción
4.
J Biol Chem ; 269(14): 10461-6, 1994 Apr 08.
Artículo en Inglés | MEDLINE | ID: mdl-8144630

RESUMEN

Unlike the muscle protein, alpha-tropomyosin expressed in Escherichia coli does not bind actin, does not exhibit head-to-tail polymerization, and does not inhibit actomyosin ATPase activity in the absence of troponin. The only chemical difference between recombinant and muscle tropomyosins is that the first methionine is not acetylated in the recombinant protein (Hitchcock-De-Gregori, S.E., and Heald, R. W. (1987) J. Biol. Chem. 262, 9730-9735). We expressed three fusion tropomyosins in E. coli with 2, 3, and 17 amino acids fused to its amino terminus. All three fusions restored actin binding, head-to-tail polymerization, and the capacity to inhibit the actomyosin ATPase to these unacetylated tropomyosins. Unlike larger fusions, the small fusions of 2 and 3 amino acids do not interfere with regulatory function. Therefore the presence of a fused dipeptide at the amino terminus of unacetylated tropomyosin is sufficient to replace the function of the N-acetyl group present in muscle tropomyosin. A structural interpretation for the function of the acetyl group, based on our results and the coiled coil structure of tropomyosin, is presented.


Asunto(s)
Dipéptidos/genética , Tropomiosina/genética , Actinas/metabolismo , Actomiosina/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , ATPasa de Ca(2+) y Mg(2+)/antagonistas & inhibidores , ATPasa de Ca(2+) y Mg(2+)/metabolismo , Pollos , Clonación Molecular , Dipéptidos/metabolismo , Escherichia coli , Datos de Secuencia Molecular , Oligodesoxirribonucleótidos , Proteínas Recombinantes de Fusión/metabolismo , Tropomiosina/química , Tropomiosina/metabolismo , Troponina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA